Cargando…

Case Report: A good response to furmonertinib second-line treatment of an advanced lung adenocarcinoma patient with a rare EGFR exon 20 N771_P772insH mutation: A case report and literature review

Background: Lung adenocarcinoma with the classical EGFR 19 deletion and exon 21 L858R point mutations has exhibited good responses to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment. However, the sensitivity of uncommon EGFR exon 20 insertion mutation to third-gener...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Xiao, Han, Huan, Zhao, Jiuzhou, Liu, Xiao, Zhang, Jianbo, Sun, Rui, Li, Shaomei, Liu, Baoxing, Zhu, Hui, Jiao, Shuyue, Li, Xiang, Tang, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9432720/ https://www.ncbi.nlm.nih.gov/pubmed/36059942 http://dx.doi.org/10.3389/fphar.2022.964606

Ejemplares similares

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
por: Chen, Xuesong, et al.
Publicado: (2023)

Combination effects of ellagic acid with erlotinib in a Ba/F3 cell line expressing EGFR H773_V774 insH mutation
por: Xie, Chuanqi, et al.
Publicado: (2020)

Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report
por: Ma, Xiaoting, et al.
Publicado: (2023)

Advanced lung adenocarcinoma patient with EGFR exon 20 insertion benefits from high-dose furmonertinib for nine months after progression from mobocertinib: a case report
por: Jia, Keyi, et al.
Publicado: (2022)

Case Report: Osimertinib Followed by Osimertinib Plus Bevacizumab, Personalized Treatment Strategy for a Lung Cancer Patient With a Novel EGFR Exon 20 Insertion D770_N771insGT and Multiple Brain Metastases
por: Zhi, Xiaoyu, et al.
Publicado: (2021)

Successful therapy using high-dose furmonertinib for non-small cell lung cancer with leptomeningeal metastasis: a case report and literature review
por: Chen, Ting, et al.
Publicado: (2023)

Charmonium production at FNAL/E771
por: Elia, V, et al.
Publicado: (1998)

Case report: sequential use of almonertinib based on the EGFR exon 20 insertion mutation achieves long-term control for advanced non-small cell lung cancer patients
por: Wang, Ruilin, et al.
Publicado: (2022)

Case Report: Partial Response Following Nivolumab Plus Docetaxel in a Patient With EGFR Exon 20 Deletion/Insertion (p.N771delinsGF) Mutant Lung Adenocarcinoma Transdifferentiated From Squamous Cell Carcinoma
por: Zhu, Lingling, et al.
Publicado: (2022)

Successful salvage therapy using high-dose furmonertinib (AST2818) for non–small-cell lung cancer after Osimertinib resistance: a case report
por: Cheng, Daoan, et al.
Publicado: (2022)

Efficient Synthesis of Potential Impurities in Levonadifloxacin (WCK 771)
por: Kilbile, Jaydeo T., et al.
Publicado: (2021)

771 Enzymatic Burn Wound Debridement: The Learning Curve
por: Mertz, Tamara, et al.
Publicado: (2023)

Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS
por: Li, Ying, et al.
Publicado: (2022)

Successful treatment of a lung adenocarcinoma patient with a novel EGFR exon 20-ins mutation with afatinib: A case report
por: Cai, Yangyang, et al.
Publicado: (2019)

ARV-771 Acts as an Inducer of Cell Cycle Arrest and Apoptosis to Suppress Hepatocellular Carcinoma Progression
por: Deng, Yuanfei, et al.
Publicado: (2022)

Report of Am. Ins. of Homœopathy
por: Lippe, Ad.
Publicado: (1881)

772 Impact of Clinical Course on Psychosocial Outcomes in Adult Burn Survivors
por: Ross, Erin E, et al.
Publicado: (2022)

Annual assessment of Echinococcus multilocularis surveillance reports submitted in 2019 in the context of Commission Delegated Regulation (EU) 2018/772
por: Zancanaro, Gabriele
Publicado: (2019)

Annual assessment of Echinococcus multilocularis surveillance reports submitted in 2020 in the context of Commission Delegated Regulation (EU) 2018/772
por: Zancanaro, Gabriele
Publicado: (2021)

Annual assessment of Echinococcus multilocularis surveillance reports submitted in 2021 in the context of Commission Delegated Regulation (EU) 2018/772
por: Zancanaro, Gabriele
Publicado: (2021)

Annual assessment of Echinococcus multilocularis surveillance reports submitted in 2022 in the context of Commission Delegated Regulation (EU) 2018/772
por: Zancanaro, Gabriele
Publicado: (2022)

Annual assessment of Echinococcus multilocularis surveillance reports submitted in 2023 in the context of commission delegated regulation (EU) 2018/772
por: Rusinà, Alessia, et al.
Publicado: (2023)

Good response with durvalumab after chemoradiotherapy for epidermal growth factor receptor exon 20 insertion adenocarcinoma: A case report
por: Matsuura, Shun, et al.
Publicado: (2020)

771 Improving Burn Care in the Amish Community: A Qualitative Study of Strengths and Needs
por: Brumbaugh, Jamey T, et al.
Publicado: (2022)

771. The impact of infectious diseases research involvement on future infectious disease fellowship application
por: Marcus, Joseph, et al.
Publicado: (2023)

ZYZ-772 Prevents Cardiomyocyte Injury by Suppressing Nox4-Derived ROS Production and Apoptosis
por: Wang, Ying, et al.
Publicado: (2017)

772. Factors Associated With Healthcare Delay of Active Pulmonary Tuberculosis After Hospitalization
por: Han, Jaijun, et al.
Publicado: (2018)

772. Learning from our patients: An exploratory study to inform the development of a case tracking dashboard for subspecialty fellows
por: Minter, Daniel J, et al.
Publicado: (2023)

Intracranial efficacy and safety of furmonertinib 160 mg with or without anti-angiogenic agent in advanced NSCLC patients with BM/LM as salvage therapy
por: Xu, Ziyi, et al.
Publicado: (2023)

Draft Genome Sequence of Methicillin-Resistant Staphylococcus aureus KT/Y21, a Sequence Type 772 (ST772) Strain Isolated from a Pediatric Blood Sample in Terengganu, Malaysia
por: Suhaili, Zarizal, et al.
Publicado: (2014)

C771G (His241Gln) Polymorphism of MLXIPL Gene, TG levels and coronary artery disease: A case control study
por: Ghasemi, Asghar, et al.
Publicado: (2015)

Birt-Hogg-Dubé syndrome with c.1579_1580insA variant in a Chinese family: a case report
por: Tang, Shijie, et al.
Publicado: (2023)

Case report: A 10-year prognosis of neonatal diabetes caused by a novel INS gene mutation
por: Tian, Mengting, et al.
Publicado: (2023)

Proposal for the award of a contract for the construction work for the new Building 771 "Polymer Laboratory" on the Prévessin site
Publicado: (2015)

Is the 77.1 % rate of in-hospital mortality in patients receiving venoarterial extracorporeal membrane oxygenation really that high?
por: Shimizu, Kentaro, et al.
Publicado: (2016)

771 Can Human Bocavirus mRNA Detection Differentiate Acute Infection from Viral Shedding?
por: Schlaberg, Robert, et al.
Publicado: (2014)

EO771, is it a well‐characterized cell line for mouse mammary cancer model? Limit and uncertainty
por: Le Naour, Augustin, et al.
Publicado: (2020)

Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, “uncommon-G719X, S768I, L861Q”) Among the Third-Generation EGFR TKIs?
por: Zhang, Shannon S, et al.
Publicado: (2022)

Exon 2: Is it the good police in familial mediterranean fever?
por: Bilge, Şule Yaşar, et al.
Publicado: (2019)

Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells
por: Wu, Chung-Pu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_qfcu75al6ctubq08dq3fp128u8